Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Numerous research reports have witnessed dramatic advancements in cancer therapeutic
approaches through immunotherapy. Blocking immunological checkpoint pathways …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …

Several proteins and peptides have therapeutic potential and can be used for cancer
therapy. By binding to cell surface receptors and other indicators uniquely linked with or …

Background The introduction of immunotherapy in the treatment of non-small cell lung
cancer (NSCLC) has resulted in a radical change in patients' treatment responses and …

Non-small cell lung cancer (NSCLC) is largely promoted by a multistep tumorigenesis
process involving various genetic and epigenetic alterations, which essentially contribute to …

The availability of agents targeting the programmed cell death protein 1 (PD‐1)/programmed
death‐ligand 1 (PD‐L1) immune checkpoint has transformed treatment of advanced and/or …

The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is
critical in cancer immunity. Autophagy is a highly conserved process that is responsible for …

Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related deaths
globally. Immune checkpoint blockade (ICB) has transformed cancer medicine, with anti …

Background Non-small cell lung cancer (NSCLC) accounts for almost 85% of lung cancer-
related deaths worldwide. **huang Pill (XHP) is a representative anticancer Chinese …